cache

Home cache
  • Next Post
  • Previous Post

cache

David Dornan, PhD

/ Uncategorized

Share the Post

About the Author

Related Posts

Aadi Bioscience to Present at Ladenburg Thalmann 2021 Virtual Healthcare Conference
Aadi Bioscience to Participate in H.C. Wainwright’s 2nd Annual Precision Oncology Conference 2021
Aadi Bioscience Announces U.S. Commercial Launch and Availability of FYARRO™ for the Treatment of Adult Patients with Locally Advanced Unresectable or Metastatic Malignant PEComa
Aadi Bioscience to Participate in Upcoming Investor Conferences
AADi Announces Licensing Agreement with Celgene for Nanotechnology-Based Drug Candidate
Management of adverse events in the AMPECT trial of nab-sirolimus for the treatment of advanced malignant perivascular epithelioid cell neoplasm (PEComa)
Aadi Bioscience Announces FDA Acceptance and Priority Review for the New Drug Application of FYARRO™ for the Treatment of Advanced Malignant PEComa
ABI-009, nab-Sirolimus, an mTOR Inhibitor with High Lung Accumulation in Preclinical Models: Initial Results from an Ongoing Phase I/II Safety and Preliminary Efficacy Study in Severe PAH

Comments

Comments are closed.

  • Next Post
  • Previous Post